SynthesisFrontiers in immunology2026
Immunotherapy for TKI-resistant, EGFR L858R-mutated non-small cell lung cancer: a systematic review and meta-analysis of randomized and single-arm studies.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immune checkpoint inhibitor-related thyroid dysfunction during treatment of lung cancer: a disproportionality analysis based on the FDA adverse event reporting system.Frontiers in immunology · 2026Article
- Dynamic clonal evolution of multiple bypass resistance mechanisms inFrontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The application of immune checkpoint inhibitors (ICIs) in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) following tyrosine kinase inhibitor (TKI) resistance remains controversial. Prior studies often obscured immunobiological heterogeneity by analyzing exon 19 deletions and L858R mutations in aggregate. This study conducts the first meta-analysis specifically focusing on the EGFR L858R subtype to systematically evaluate ICI efficacy (monotherapy vs. combinations) in the post-TKI setting. Methods: We systematically searched PubMed, EMBASE, Cochrane, and Web of Science (up to January 1, 2026) for studies on ICI-treated EGFR-mutated NSCLC. Prospective or retrospective studies explicitly reporting L858R data were selected. Primary endpoints included progression-free survival (PFS) and objective response rate (ORR); the secondary endpoint was overall survival (OS). Given that our meta-analysis includes both randomized controlled trials and single-arm studies, we explicitly stratified analyses by study design. RCTs provide comparative estimates, whereas single-arm studies are descriptive and exploratory; pooled results from single-arm studies should not be interpreted as definitive evidence of efficacy. Pooled hazard ratios (HRs) were calculated using a random-effects model, stratified by treatment modality. Results: Seventeen studies involving 1, 154 patients were included. Compared with chemotherapy, ICI-based treatments significantly improved PFS [HR = 0.63, 95% confidence intervals (CI):0.44-0.90, P = 0.01]. Subgroup analysis revealed significant disparities: ICI monotherapy failed to confer a PFS benefit (HR = 1.68, 95% CI:0.94-2.99, P = 0.08), whereas combination therapies were effective. Exploratory analyses from non-comparative single-arm studies supported these trends, showing higher ORR and PFS for combination regimens than for monotherapy. Notably, the "ICI plus anti-angiogenic agents plus chemotherapy" regimen exhibited the optimal PFS benefit (HR = 0.50, P<0.01), outperforming "ICI plus chemotherapy" (HR = 0.57, P = 0.02). Combination therapy also yielded superior ORR. However, no statistically significant OS advantage was observed for ICI treatment versus chemotherapy (HR = 0.97, P = 0.83). Conclusion: For EGFR-TKI-resistant, L858R-mutated NSCLC, ICI monotherapy appears ineffective. Conversely, ICI-based combinations-particularly the four-drug regimen incorporating anti-angiogenic agents-significantly delay disease progression and improve response rates. Future research should prioritize prospective studies and novel agents, such as antibody-drug conjugates, to improve long-term survival. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/, identifier CRD420261278330.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.